CML Community Advisory Board (CML-CAB) Meeting 2021
On 18 February 2021, the CML Community Advisory Board (CML-CAB), a workgroup of the CML Advocates Network, hosted it´s first meeting of the year. It was the 12th CML Community Advisory Board (CML-CAB) and 22nd CML-CAB session. The main objective of this meeting with Novartis which took place in a virtual format and whose focus was on “Future Treatments and Current Access” were to foster a mutual understanding and to take tangible actions forward for Novartis, the patient community and both in collaboration. Main focus of the meeting was asciminib (ABL001) – Novartis´ novel investigational treatment that specifically targets the ABL myristoyl pocket (STAMP). Topics discussed during the meeting included the Asciminib Development Program (incl. Patient Reported Outcomes measures and Quality of Life), its value proposition and positioning of the drug, as well as Novartis´ global access strategy for asciminib.
Executive Summary 12th CML-CAB: Virtual meeting, 18 February 2021